347 related articles for article (PubMed ID: 24039177)
21. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
[TBL] [Abstract][Full Text] [Related]
22. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology.
Savic S; Franco N; Grilli B; Barascud Ade V; Herzog M; Bode B; Loosli H; Spieler P; Schönegg R; Zlobec I; Clark DP; Herman JG; Bubendorf L
Chest; 2010 Jul; 138(1):137-44. PubMed ID: 20139227
[TBL] [Abstract][Full Text] [Related]
23. Analysis of early pleural fluid samples in patients with mesothelioma: A case series exploration of morphology, BAP1, and CDKN2A status with implications for the concept of mesothelioma in situ in cytology.
Louw A; van Vliet C; Peverall J; Colkers S; Acott N; Creaney J; Lee YCG; Chai SM
Cancer Cytopathol; 2022 May; 130(5):352-362. PubMed ID: 35143119
[TBL] [Abstract][Full Text] [Related]
24. Adenomatoid mesothelioma with intranuclear inclusion bodies: a case report with cytological and histological findings.
Kawai T; Kawashima K; Serizawa H; Miura H; Kyeongil K
Diagn Cytopathol; 2014 May; 42(5):436-40. PubMed ID: 23166110
[TBL] [Abstract][Full Text] [Related]
25. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
[TBL] [Abstract][Full Text] [Related]
26. Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma.
Siddiqui MT; Schmitt F; Churg A
J Am Soc Cytopathol; 2019; 8(6):352-361. PubMed ID: 31495751
[TBL] [Abstract][Full Text] [Related]
27. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
28. Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology.
Andrici J; Sheen A; Sioson L; Wardell K; Clarkson A; Watson N; Ahadi MS; Farzin M; Toon CW; Gill AJ
Mod Pathol; 2015 Oct; 28(10):1360-8. PubMed ID: 26226841
[TBL] [Abstract][Full Text] [Related]
29. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
30. Positive pleural cytology is an indicator for visceral pleural invasion in metastatic pleural effusions.
Froudarakis ME; Plojoux J; Kaspi E; Anevlavis S; Laroumagne S; Karpathiou G; Roca E; Adler D; Dutau H; Astoul P
Clin Respir J; 2018 Mar; 12(3):1011-1016. PubMed ID: 28245530
[TBL] [Abstract][Full Text] [Related]
31. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.
Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
J Clin Pathol; 2013 Oct; 66(10):847-53. PubMed ID: 23814259
[TBL] [Abstract][Full Text] [Related]
32. Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology.
Jo VY; Cibas ES; Pinkus GS
Cancer Cytopathol; 2014 Apr; 122(4):299-306. PubMed ID: 24421209
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
[TBL] [Abstract][Full Text] [Related]
34. Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples.
Monaco S; Mehrad M; Dacic S
Adv Anat Pathol; 2018 Jan; 25(1):24-30. PubMed ID: 29227332
[TBL] [Abstract][Full Text] [Related]
35. Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy - Data supporting 'Direct to LAT' in selected groups.
Tsim S; Paterson S; Cartwright D; Fong CJ; Alexander L; Kelly C; Holme J; Evison M; Blyth KG
Lung Cancer; 2019 Jul; 133():123-129. PubMed ID: 31200818
[TBL] [Abstract][Full Text] [Related]
36. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
[TBL] [Abstract][Full Text] [Related]
37. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
Onofre FB; Onofre AS; Pomjanski N; Buckstegge B; Grote HJ; Böcking A
Cancer; 2008 Jun; 114(3):204-15. PubMed ID: 18306350
[TBL] [Abstract][Full Text] [Related]
38. State-of-the-art cytology of pleural fluid, focusing on the diagnosis of mesothelioma.
Monaco SE; Brcic L; Dacic S
Cytopathology; 2022 Jan; 33(1):57-64. PubMed ID: 34467576
[TBL] [Abstract][Full Text] [Related]
39. Cytologic re-evaluation of negative effusions from patients with malignant mesothelioma.
Ascoli V; Bosco D; Carnovale Scalzo C
Pathologica; 2011 Dec; 103(6):318-24. PubMed ID: 22558888
[TBL] [Abstract][Full Text] [Related]
40. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N
Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
